

12-22-99

A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Express Mail[®] Mailing Label No. EL41705259USDate of Deposit 12/21/99Docket No. WELD 111 DIV IVJC564 U.S. PTO
09/468496

12/21/99

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Prior Application:

Examiner: S. GilbertArt Unit: 3736Name ARMANDO CHING

(typed or printed)

Signature Armando Ching

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This is a request for filing a [] continuation
[X] divisional application of pending prior application Serial No.
08/897,358 filed on July 21, 1997, which is a continuation of
Serial No. 08/330,327 filed on October 27, 1994, for METHOD AND
APPARATUS FOR TREATING A DESIRED AREA IN THE VASCULAR SYSTEM OF A
PATIENT.

1. Enclosed is a copy of the prior application, including the oath or declaration as originally filed.

I hereby verify that the attached papers are a true copy of prior application Serial No. 08/330,327 as originally filed on October 27, 1994 and further that this statement is made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false

statements may jeopardize the validity of the application or any patent issuing thereon.

2. ☒ The filing fee is calculated below pursuant to the claims as filed in the prior application:

a. ☐ less any claims canceled by Amendment below.

b. ☒ after entering the attached Preliminary Amendment.

☒ Small Entity

For	Number Filed	Number Extra	Rate	Fee
Total Claims	12	-	x \$ 9	\$ -
Independent Claims	4	1	x \$39	\$ 39.00
Multiple Dependent Claims (minimum fee - additional charge may be due under total claim calculation - See 37 CFR §§ 1.16(d) and 1.75(c))			\$130	
Basic Fee (minimum amount required)				\$380.00
Total Filing Fee				\$419.00

☐ Other than Small Entity

For	Number Filed	Number Extra	Rate	Fee
Total Claims		-	x \$18	\$ -
Independent Claims		-	x \$78	\$ -
Multiple Dependent Claims (minimum fee - additional charge may be due under total claim calculation - See 37 CFR §§ 1.16(d) and 1.75(c))			\$260	
Basic Fee (minimum amount required)				\$760.00
Total Filing Fee				

3. ☒ The Commissioner is hereby authorized to charged any additional fees which may be required, or credit any overpayment to Account No. 50/1039. A duplicate copy of this sheet is enclosed.
4. ☒ A check in the amount of \$419.00 is enclosed.
5. ☐ Cancel in this application original claims _____ and _____ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing.)
- ☒ Enter the enclosed Preliminary Amendment prior to calculating the filing fee.
6. ☐ Amend the specification by inserting before the first line the sentence: --This is a ☐ continuation, ☒ division, of application Serial No. / , filed .--
- ☒ Amend the specification per the attached Preliminary Amendment.
7. ☐ Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file. (May only be used if signed by person authorized by 37 C.F.R. § 1.138 and before payment of base issue fee.)

- ☒ New formal drawings are enclosed.
- ☐ Informal drawings are enclosed.
8. ☐ Priority of application serial no. _____
filed on _____ in _____
is claimed under 35 U.S.C. § 119.
- ☐ The certified copy of the priority application has
been filed in prior application serial no. _____
_____, filed _____.
9. ☒ With respect to the prior co-pending U.S.
application from which this application claims
benefit under 35 U.S.C. § 120 the inventor(s) in
this application are:
- a. ☐ the same.
- b. ☒ less than those named in the prior
application and it is requested that the
following inventor(s) for the prior
application be deleted:
Ian R. Crocker, Raphael F. Meloul
10. ☐ The inventorship for all the claims in this
application is:
- a. ☐ the same.
- b. ☐ not the same, and an explanation,
including the ownership of the various
claims at the time the last claimed
invention was made, is submitted.

11. [X] The prior application is assigned of record to
Novoste Corporation.

12. [X] The power of attorney in the prior application is
to: Stephen B. Heller, registration no. 30,181 of
Cook, Alex, McFarron, Manzo,
Cummings & Mehler, Ltd.
200 West Adams Street, Suite 2850
Chicago, IL 60606

a. [X] The power appears in the original papers
in the prior application.

b. [] Since the power does not appear in the
original papers, a copy of the power in
the prior application is enclosed.

c. [X] Address all future communications to:

Stephen B. Heller
Cook, Alex, McFarron, Manzo, Cummings
& Mehler, Ltd.
200 West Adams Street - Suite 2850
Chicago, IL 60606

Respectfully submitted,

Date: December 21, 1999

Stephen B. Heller
Stephen B. Heller
Registration No. 30,181

COOK, ALEX, MCFARRON, MANZO,
CUMMINGS & MEHLER, LTD.
200 West Adams Street
Suite 2850
Chicago, Illinois 60606
(312)236-8500

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Express Mail Mailing Label No. EL411705259US

In Re Application of:
WAKSMAN, ET AL.

Serial No.:

Filed: Herewith

For: METHOD AND APPARATUS FOR
TREATING A DESIRED AREA IN
THE VASCULAR SYSTEM OF A
PATIENT

) Date of Deposit 12/21/99

) I hereby certify that this paper or fee is being
) deposited with the United States Postal Service
) "Express Mail Post Office to Addressee" and
) under 37 CFR 1.10 on the date indicated above
) and is addressed to the Assistant Commissioner
) for Patents, Washington, D.C. 20231

) Name ARMANDO CEBEN
) (typed or printed)

Signature Armando Ceben

VERIFIED STATEMENT CLAIMING SMALL ENTITY
STATUS -- SMALL BUSINESS CONCERN

Honorable Commissioner of Patents & Trademarks
Washington, D.C. 20231

Dear Examiner:

I hereby declare that I am:

_____ the owner of the small business concern identified below:

X an official of the small business concern empowered to
act on behalf of the concern identified below:

NAME OF CONCERN Novoste Corporation

ADDRESS OF CONCERN 3890 Steve Reynolds Blvd.

Norcross, GA 30093

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third-party or parties controls or has the power to control both.

I hereby declare that the exclusive rights under contract or law have been conveyed, to and remain with the small business concern identified above with regard to the invention, entitled:

METHOD AND APPARATUS FOR TREATING A DESIRED AREA IN THE VASCULAR SYSTEM OF A PATIENT

by inventor(s): Ron Waksman, Thomas D. Weldon,
Richard A. Hillstead, Jonathan J. Rosen, Charles E. Larsen

described in:

 X the specification filed herewith.
 application serial no. 0 / , filed .
 patent no. , issued .

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small business entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING David N. Gill

TITLE OF PERSON OTHER THAN OWNER Chief Oper. Officer

ADDRESS OF PERSON SIGNING 3890 Steve Reynolds Blvd.

Norcross, Georgia 30093

SIGNATURE

David N. Gill

Date

12/16/99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Ron Waksman, M.D., et al.

Serial No.:

Filed:

Examiner:

Art Unit:

For: METHOD AND APPARATUS FOR
TREATING A DESIRED AREA IN
THE VASCULAR SYSTEM OF A
PATIENT

) "Express Mail" Mailing Label No. EL411705259US

) Date of Deposit 12/21/99

) I hereby certify that this paper or fee is being
) deposited with the United States Postal Service
) "Express Mail Post Office to Addressee" service
) under 37 CFR 1.10 on the date indicated above
) and is addressed to the Assistant Commissioner
) for Patents, Washington, D.C. 20231

) Name Armando C. Lugo
) (typed or printed)

) Signature Armando C. Lugo

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sir/Madam:

Please amend the above-identified application as follows:

IN THE SPECIFICATION:

Please amend the specification as follows:

On page 1, line 1, please insert

--CROSS REFERENCE TO RELATED APPLICATION--

This application is a division of Serial No. 08/897,358, filed
July 21, 1997, which is a continuation of application Serial No.
08/330,327, filed October 27, 1994.

IN THE CLAIMS:

Please cancel Claims 1-28.

Please add the following new claims.

29 (New). A catheter for use in a system for intraluminal treatment of a selected site in a body of a patient by at least one treating element movable in the catheter by means of pressurized fluid, the catheter comprising:

5 a first elongated tube having a lumen closed at its distal end and sized to slidably receive the treating element;

 a second elongated tube in parallel relation to the first elongated tube and having a lumen open at its distal end and sized to receive a guidewire; and

10 a third elongated tube for receiving the first and second elongated tubes and defining a space between the third tube and the first and second tubes, the space comprising a fluid return lumen in fluid communication with the lumen of the first elongated tube at the distal end thereof.

30 (New). The catheter of Claim 30 wherein the distal end of the third tube extends beyond the distal ends of the first and second tubes.

31 (New). The catheter of Claim 30 wherein the distal end of the second tube is coterminous with the distal end of the third tube, both of which extend beyond the distal end of the first tube.

32 (New). The catheter of Claim 30 wherein the lumen of the first elongated tube has an inside diameter less than twice the outside diameter of the treating element.

33 (New). The catheter of Claim 30 wherein the first elongated tube includes an internal barrier to block the passage of the treating element out of the first tube.

34 (New). The catheter of Claim 33 wherein fluid communication between the first and third tubes is established by an aperture in the internal barrier.

35 (New). The catheter of Claim 30 wherein the distal end of the third elongated tube is tapered.

36 (New). A catheter for use in a system for intraluminal treatment of a selected site in a body of a patient by at least one treating element moveable in the catheter by means of pressurized fluid, the catheter comprising:

a first elongated tube having a lumen sized to slidably receive the treating element;

a second elongated tube coaxial with and spaced apart from the first elongated tube, the second elongated tube extending beyond the distal end of the first elongated tube and having a barrier located in the second tube beyond the end of the first tube to close the second tube and block further distal movement of the treating element, the space between the first elongated tube and the second elongated tube defining a fluid return lumen.

37 (New). The catheter of Claim 31 wherein the distal end of the outer tube tapers to a narrow, flexible atraumatic tip.

38 (New). The catheter of Claim 36 wherein the barrier is located at the distal end of the outer tube.

39 (New). A catheter for use in a system for intraluminal treatment of a selected site in a body of a patient by at least one treating element moveable in the catheter by means of pressurized fluid, the catheter comprising:

5 first, second, and third elongated coaxial tubes extending the full length of the catheter, the first tube comprising the innermost tube and having a lumen for receiving a guide wire open at its distal end; the first tube being spaced from the second tube to define a passageway for treating elements and the third tube spaced from the second tube to define a passageway for fluid
10 return, the distal ends of the second and third tubes communicating with each other at their distal ends; and a plug bonded to the ends of the second and third tubes to prevent passage of treating elements from the catheter.

40 (New). A catheter for use in a system for intraluminal treatment of a selected site in a body of a patient by at least one treating element moveable in the catheter by means of pressurized fluid, the catheter comprising an elongated tube with a through lumen sized to slidably receive the treating element, and a retention projection at the distal end of the tube to block passage of treating elements from the catheter, the projection having a rounded external surface.


REMARKS

This Preliminary Amendment is being filed simultaneously with the accompanying divisional application.

In the Preliminary Amendment, a cross reference to the related application has been added, Claims 1-28 filed in the grandparent case have been cancelled, and new Claims 29-40 have been added.

5 The grandparent application was subject to a restriction requirement dated September 29, 1995, in which the Examiner asserted that there were 21 patentably distinct species disclosed. The claims pending after entry of this Preliminary Amendment are directed to the catheters of Figs. 4-9.

Respectfully submitted,



Stephen B. Heller
Registration No. 30,181

COOK, ALEX, MCFARRON, MANZO,
CUMMINGS & MEHLER, LTD.
200 West Adams Street
Suite 2850
Chicago, Illinois 60606
(312)236-8500

TITLE:

METHOD AND APPARATUS FOR TREATING A DESIRED AREA
IN THE VASCULAR SYSTEM OF A PATIENT

EF87285385

"Express Mail" Mailing Label No. _____

INVENTORS:

Date of Deposit 10-27-94

RON WAKSMAN, M.D.
THOMAS D. WELDON
RICHARD A. HILLSTEAD
JONATHAN J. ROSEN
CHARLES E. LARSEN
IAN R. CROCKER, M.D.
RAPHAEL F. MELOUL

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Name Angel Defina
(typed or printed)

FIELD OF THE INVENTION

Signature Angel Defina

The present invention relates generally to the delivery of treating elements by a catheter to a selected site within the vascular system of a patient. More particularly, the present invention relates to method and apparatus for the delivery of a treating element, such as a radiation source, through a catheter to a desired site, such as a coronary artery, for inhibiting wound healing response, such as restenosis following balloon angioplasty.

BACKGROUND OF THE INVENTION

It is known that the human body's healing response to wounds typically includes the formation of what is commonly called scar tissue. This response also occurs within the vascular system of a person following injury to a blood vessel. An injury that provokes the formation of scar tissue may occur in various locations within the vascular system, such as in the carotid artery or in coronary bypasses, or in various ways, such as trauma from surgical or diagnostic procedures.

One area of the vascular system of particular concern with respect to such injuries is coronary arteries that are subjected to procedures for removing or reducing blockages due to plaque within the arteries. Partial and even complete blockage of coronary arteries by the formation of an atherosclerotic plaque is a well known and frequent medical problem. Such blockages may

be treated using atherectomy devices, which mechanically remove the plaque; hot or cold lasers, which vaporize the plaque; stents, which hold the artery open; and other devices and procedures which have the objective of allowing increased blood flow through the artery. The most common such procedure is the percutaneous transluminal coronary angioplasty (PTCA) procedures -- more commonly referred to as balloon angioplasty. In this procedure, a catheter having an inflatable balloon at its distal end is introduced into the coronary artery, the uninflated balloon is positioned at the stenotic site and the balloon is inflated. Inflation of the balloon disrupts and flattens the plaque against the arterial wall, and stretches the arterial wall, resulting in enlargement of the intraluminal passageway and increased blood flow. After such expansion, the balloon is deflated and the balloon catheter removed.

PTCA is a widely used procedure and has an initial success rate of between 90 and 95 percent. However, long term success of PTCA (as well as the other artery-opening procedures referred to above) is much more limited, due largely to restenosis, or re-closing of the intraluminal passageway through the artery. Restenosis, wherein the vessel passageway narrows to approximately 50% or less of the enlarged size, is experienced in approximately 30 to 50 percent of the patients within six months after PTCA. Restenosis may occur for various reasons, but it is now believed that restenosis is, in significant part, a natural healing response to the vessel injury caused by inflation of the angioplasty balloon.

Vessel injury may occur in several ways during PTCA, including: denudation (stripping) of the endothelium (the layer of flat cells that line the blood vessels); cracking, splitting and/or disruption of the atherosclerotic plaque and intima (innermost lining of the blood vessel); dehiscence (bursting) of the intima and the plaque from the underlying media; stretching and tearing of the media and adventitia (outside covering of the artery) which may result in aneurysmal expansion; and injury to the vessel smooth muscle. Such injury to the vessel typically initiates the body's own natural repair and healing process.

During this healing process, fibrin and platelets rapidly accumulate in the endothelium, and vascular smooth muscle cells proliferate and migrate into the intima. The formation of scar tissue by smooth muscle proliferation, also known as intimal hyperplasia, is believed to be a major contributor to restenosis following balloon angioplasty of the coronary artery.

Prior attempts to inhibit restenosis of coronary arteries have included, among other things, the use of various light therapies, chemotherapeutic agents, stents, atherectomy devices, hot and cold lasers, as well as exposure of the stenotic site to radiation. These therapies have had varying degrees of success, and certain disadvantages are associated with each of these therapies. Although radiation therapy has shown promise, particularly in inhibiting intimal hyperplasia, the devices available for delivery of radiation sources to a stenotic site have been limited and have tended to suffer from drawbacks which limit their usefulness. Typical of the devices using radiation to treat restenosis are those shown or described in U.S. Patents Nos. 5,059,166 to Fischell; 5,213,561 to Weinstein; 5,302,168 to Hess, 5,199,939 to Dake; 5,084,002 to Liprie; and 3,324,847 to Zoumboulis.

SUMMARY OF THE INVENTION

The present invention is directed to apparatus and methods for delivering one or more treating elements, such as a radiation source, through a catheter to a desired location in the vascular system of a human patient and to retrieving the treating element(s) through the catheter, if so desired. The present invention is particularly applicable, but not limited, to the treatment of coronary arteries that have been or will be subjected to PTCA or other artery-opening procedures, in order to inhibit intimal hyperplasia and reduce the risk of restenosis. The present invention is also useful in other areas of the vascular system, such as in the carotid artery or in coronary bypasses.

More specifically, as set forth in the appended claims, the present invention comprises an elongated flexible catheter tube having a proximal end portion adapted to remain outside the patient's body, a distal end portion adapted to be positioned at a selected location within the vascular system of the patient and a lumen extending therebetween, with the diameter of the catheter tube being sufficiently small for insertion into the patient's vascular system. The catheter tube is preferably but not necessarily adapted for positioning the distal end of the tube at the desired site by advancement over a guide wire. A port is provided at the proximal end portion of the tube, through which blood-compatible liquid may be introduced from a source of such liquid into the lumen. One or more treating elements, which may be in the form of a solid capsule, pellet or the like, such as a capsule or pellet containing radioactive material, is positionable within the lumen and is movable between the proximal and the distal end portions of the tube under the motive force exerted by the liquid flowing through the lumen.

In accordance with the present invention, a method is also provided for treating a selected area in the vascular system of a patient wherein an elongated flexible catheter tube having a distal end portion adapted to be positioned at a selected location within the vascular system of the patient, a proximal

end portion adapted to remain outside the patient's body, a lumen extending therebetween, and a diameter sufficiently small for insertion into the patient's vascular system is introduced into the vascular system of a patient. The catheter is preferably but not necessarily introduced over a guide wire until the distal end portion of the tube is within the selected area of the vascular system. A port communicating with the first lumen is adapted for introduction of blood-compatible liquid into the lumen. One or more treating elements, such as a capsule or pellet containing radioactive material, is introduced into the lumen at the proximal end portion of the tube and is moved from the tube's proximal end portion through the lumen to the distal end portion within the selected area by flowing the blood-compatible liquid through the lumen to generate a motive force on the element so as to move it from the proximal end to the desired location at the distal end portion. There, the treating element is allowed to remain a sufficient time for treatment of the selected area, during which time the remaining portion of the catheter is free of treating elements so as to not unnecessarily expose other tissue to such treatment. After the treatment is completed, the catheter tube is removed from the patient.

In another embodiment, the present invention is embodied in an angioplasty balloon catheter having proximal and distal end portions, with a lumen extending therebetween. The lumen communicates with an inflatable balloon located on the distal end portion. In accordance with the present invention, one or more treating elements, such as a radiation source, is either carried fixedly at the balloon or moved through a lumen from the proximal end portion to the distal end portion, for delivery of radiation to the stenotic site as the angioplasty procedure is actually carried out -- therefore allowing what may otherwise be a two-step process to be carried out in a single step. From this summary, it should be apparent that the method of the present invention may be carried out before, during or after an angioplasty or other artery-opening procedure, whichever is deemed most desirable by the treating physician.

DRAWINGS

Figure 1 is a diagrammatic representation of a catheter-based treatment delivery system embodying the present invention.

5 Figure 2A is cross-sectional view of one embodiment of the proximal end portion of the treatment delivery system of the present invention.

Figure 2B is a cross-sectional view of another embodiment of the treatment delivery system of the present invention.

10 Figure 2C is a cross-sectional view of still another embodiment of the treatment delivery system of the present invention.

Figure 3 is a cross-sectional view of one embodiment of the treating elements of the present invention.

15 Figure 4 is a partial cross-sectional view of one embodiment of the elongated catheter tube of the present invention, showing the treating elements disposed in the distal end portion of the tube.

20 Figure 5 is a partial cross-sectional view of a second embodiment of the elongated catheter tube of the present invention, showing the treating elements in the distal end portion of the tube.

25 Figure 6A is a partial cross-sectional view of a third embodiment of the elongated catheter tube of the present invention, showing the treating elements in the distal end portion of the tube.

30 Figure 6B is a partial cross-sectional view of the Figure 6A embodiment of the elongated catheter tube of the present invention, disposed within an outer guiding catheter which may be used to position the catheter tube of the present invention within the body of a patient.

35 Figure 7A is a partial cross-sectional view of a fourth embodiment of the elongated catheter tube of the present invention, showing the treating elements disposed in the distal end portion of the tube.

Figure 7B is a partial cross-sectional view of the elongated catheter tube of Figure 7A taken along line 7-7B.

Figure 8A is a partial cross-sectional view of a fifth embodiment of the elongated catheter tube of the present invention, showing the treating elements in the distal end portion of the tube.

5 Figure 8B is a partial cross-sectional view of a modified version of the embodiment of the elongated catheter tube of Figure 8A, showing the treating elements in the distal end portion of the tube.

10 Figure 9 is a partial cross-sectional view of a sixth embodiment of the elongated catheter tube of the present invention showing toroidal or ring-shaped treating elements in the distal end portion of the tube.

15 Figure 10 is a partial cross-sectional view of an alternative embodiment of the present invention having an inflatable balloon and treating elements fixedly positioned on the distal end portion.

Figure 11 is a partial cross-sectional view of an alternative embodiment of the present invention having an inflatable balloon, with the treating elements disposed therein.

20 Figure 12 is a partial cross-sectional view of another alternative embodiment of the present invention having an inflatable balloon, with the treating elements movable along the catheter.

25 Figure 13 is a partial cross-sectional view of a further alternative embodiment of the present invention having an inflatable balloon, with the treating elements movable along the catheter.

30 Figure 14 is a partial cross-sectional view of another embodiment of the treatment delivery system of the present invention.

Figure 15A is a partial cross-sectional view of a further embodiment of the treatment delivery system of the present invention.

35 Figure 15B is a elevational view of part of the proximal end portion of the treating system shown in Figure 15A.

Figure 15C is a cross-sectional view taken along lines 15c-15c of Figure 15A.

Figure 16 is a partial cross-sectional view of various parts of a further embodiment of the treatment delivery system of the present invention.

Figure 17 is a partial cross-sectional view of another alternative embodiment of the present invention having an inflatable balloon, with the treating elements movable along the catheter.

Figure 18 is a partial cross-sectional view of still another alternative embodiment of the present invention having an inflatable balloon, with the treating elements movable along the catheter.

Figure 19 is a partial cross-sectional view of still another alternative embodiment of the present invention having an inflatable balloon, with the treating elements movable along the catheter.

DETAILED DESCRIPTION

Figure 1 depicts one embodiment of the present invention in general diagrammatic form for ease of initial understanding.

5 Shown in Figure 1 is an elongated catheter 2 having a proximal end portion 4, a distal end portion 6, and at least one lumen 8 extending therebetween. The catheter is sized for insertion of the distal end portion through the vascular system of a patient to a selected area to be treated, such as the site of a balloon
10 angioplasty procedure or other opening procedure, such as an atherectomy, in a coronary artery. This may be carried out, for example, by inserting the catheter percutaneously into a femoral artery and advancing the catheter over a typical guide wire 10 upwardly through the descending aorta, over the aortic arch, downwardly through the ascending aorta and into the particular
15 coronary artery that has been selected for treatment, such as a coronary artery that has been subjected to PTCA or other artery-opening procedure. Guide wires and procedures used in advancing such a catheter to the point of the angioplasty procedure are well known and will not be discussed in detail.

At the proximal end of the catheter, which is located outside the patient in a percutaneous procedure such as described above, a transporting and/or loading device 12 is provided for loading a treating element, such as a pellet or capsule
25 comprising or containing radioactive material, into the lumen 8 of the catheter 2. Additional treating elements may also be loaded such that the total length of the combined treating elements corresponds to at least the length of the stenotic area of the vasculature to be treated. The total length of the
30 combined treating elements also could be longer than the stenotic area in order to assure that the end edges of the stenotic area are also treated. This loading procedure may also be performed manually, but a mechanical loader as described in more detail later is preferred to provide better user protection against
35 radiation.

After the treating element is loaded into the lumen 8, pressurized blood-compatible liquid, such as sterile saline

solution or sterile water, is introduced via liquid source 14 through a port 16 in the proximal end of the lumen behind the treating element. Flow of liquid through the lumen pushes the treating element along the lumen to the distal end portion, which is located at the site to be treated. The liquid which provides the motive force for moving the treating element may be allowed to exit from the distal end of the catheter or may be returned in a parallel lumen provided in the catheter or may be returned via suction through the same lumen in which the treating element travels.

After the treating element is located at the desired site, the treating element is allowed to remain for a time sufficient to treat the tissue. For radiation treatment of a stenotic site, the treating element preferably are beta-emitting radiation sources, and the residence time period will be relatively short, on the order of minutes as discussed in more detail below.

After the treatment is complete, the catheter may be removed with the treating element remaining at the distal end or, alternatively, liquid may be forced through the lumen in a reverse direction to return the treating element to the proximal end and into the loading device, if desired, before removal of the catheter. The reverse flow of fluid may be achieved by forcing liquid under positive pressure through the lumen in a reverse direction or by applying a suction, such as by withdrawing the piston of a syringe attached at the proximal end of the lumen, to the lumen.

The transporting/loading device 12 need not be connected directly to the proximal end of the catheter 2 if such direct connection would result in possible kinking of the catheter or would restrict maneuverability. In that case, an additional length of tubing (which may have the same number of lumens as the catheter) could be provided between the transporting/loading device 12 and the proximal end portion of the catheter. In such event, the additional length of tubing (as well as the proximal end portion of the catheter located outside the patient) may be shielded to protect the user and/or the patient from unnecessary radiation exposure.

Figure 2A shows one actual embodiment of the proximal end of the catheter system depicted in Figure 1. Although not limited to use with radioactive treating elements, the device shown in Figure 2A is particularly adapted for that application.

Specifically, Figure 2A depicts a three-lumen catheter system 18 with a loading device 20 containing treating elements 22 and connected to the proximal end of a three lumen catheter tube 24. The loading device comprises a rigid body 26 preferably of a suitable rigid polymer, having a proximal end 28, a distal end 30 and a first, a second and a third bore, 32, 34 and 36 respectively, extending therebetween. A fitting 38 located at the distal end of the body connects the first, second and third bores, respectively, with one of the three lumens 33, 35 and 37 of the catheter tube 24.

At the proximal end of the housing member, ports, such as luer connector ports, are provided for communication with bores 32, 34 and 36. A first port 40 is aligned with the first bore 32 of the body and is adapted for the entry or exit of a liquid, such as sterile saline. A second port 42 is in communication with the second bore 34 of the housing member and is likewise adapted to permit the entry or exit of liquid into the body. The third port 44 opens into the third bore of the body and is adapted to receive a guide wire 46 to aid in positioning the distal end of the catheter tube within a patient. A valve (not shown), such as a Touhy-Borst valve, may be attached to the third port to prevent leakage of fluid around the guide wire during or after insertion of the device into the patient.

For loading and/or unloading of the treating elements 22, a retaining device such as a magazine, carrier or carriage 48 is slidably positioned within a slot 50 defined in the body 26 intermediate the proximal and distal ends. The carriage is preferably constructed of the same material as the rigid body 26 and has a first through bore 52 and a second through bore 54. The first and second through bores of the carriage may be selectively aligned with the first bore 32 of the body, depending upon the lateral position of the carriage relative to the body. A carriage with only a single through bore may also be used.

By pre-loading the treating elements into the carriage, they may be conveniently handled, shipped and stored separate from the rest of the loading device. When the user is ready for the procedure, the carriage may be simply inserted into the body, thereby minimizing handling of the treating elements by and exposure to the user. The carriage is preferably made of a material and has sufficient thickness to protect the user against unnecessary exposure to radiation when the treating elements are radioactive.

As shown in Figure 2A, carriage 48 is fully inserted into the body 26, with the first bore 52 of the carriage aligned with the first bore 32 of the body. In this position, second bore 54 of the carriage contains the treating elements 22 and is positioned within the body, thereby providing protection of the user from radiation emitted by the treating elements. In this first position, fluid, such as sterile saline, may be introduced through the first port to prime the body and catheter and remove any air contained therein, if so desired.

By sliding the carriage 48 outwardly from the body 26, the carriage is moved into a second position wherein second bore 54 of the carriage is coaxially aligned with first bore 32 of the body, and the treating elements 22 are ready for introduction into the catheter 24. In this second position, pressurized liquid, such as sterile saline, may be introduced via pump 14 through first port 40 to supply the motive force against the treating elements 22, ejecting them from second through bore of the carriage, distally through the first bore 32 of the body, and into a lumen of the catheter.

The specific design of the pump 14 may be chosen from various alternatives. For example, the pump 14 may be a simple saline-filled piston syringe attached via luer lock connector to port 40 of body 26. Manual depression of the syringe plunger would provide sufficient force to eject the treating elements and move them to the desired position in the catheter (and withdrawal of the plunger may assist in returning the treating elements to the proximal end portion after the treatment is complete). Alternatively, the motive force may be provided by a column of

liquid from a suspended container of sterile saline or water, controlled by a simple roller clamp or stopcock.

Alternative configurations for the carriage (not shown) also may be used without departing from the scope of the present invention. For example, the carriage may be cylindrical and/or rotatably mountable within the body. Through bores or chambers within the carriage may be selectively brought into alignment with the bores of the body by rotating the carriage. The treating elements may be pre-loaded in the cylinder to minimize user contact and to protect the user from radiation when a radioactive treating element is employed. By providing the treating elements 22 pre-loaded into a loading device 20 or pre-loaded into a carriage 48 that may be inserted into a loading device, user contact with the treating elements is minimized, and for radioactive treating elements, the user may be shielded from radiation.

Figure 2B shows a further alternative embodiment of a catheter system of the present invention. Catheter system 56 includes a combination loading device and pump 58 and a multi-lumen catheter 60. The combination pump and loading device comprises a body portion 62 having a distal end portion 64 attached to the elongated catheter tube and a proximal end portion 66 mounting connectors for fluid communication with passageways defined in the body.

The body portion 62 has a central bore or passageway 68 in which treating elements 22 are located prior to the treatment and after the treatment is completed. The central bore 68 communicates directly with one of the lumens of multi-lumen catheter 60. Discharge of the treating elements from the bore 68 is controlled by gate 70, which may be moved between positions blocking flow or allowing flow through central bore. Alternatively, the gate may contain openings of sufficiently small size to permit fluid to pass therethrough, while preventing passage of the treating elements while the gate blocks the central bore. This aids in priming the system with the treating elements in position in bore 68, if so desired.

For providing the pressurized flow of liquid to transport treating elements to and from the distal end of catheter 60, a pair of piston-cylinder arrangements are provided on opposite sides of the body portion 62. Piston-cylinder arrangement 72 provides the liquid flow for dispatching the treating elements to the distal end of the catheter and piston-cylinder arrangement 74 provides the reverse liquid flow for retrieving the treating elements therefrom.

Interior passageway 76 in the body 62 communicates between liquid inlet port 78, central bore 68 and the cylinder of dispatch piston-cylinder arrangement 72, which provides the fluid flow for moving the treating elements into and along a principal lumen of the catheter 60. One-way, spring loaded ball valve 80 within passageway permits liquid to enter through the inlet port but blocks liquid from exiting from the port. Vent 79 allows displacement air to exit from the passageway 76 when liquid is added, for priming purposes and the like, and a pressure relief valve 81 may be provided to prevent overpressurization of the catheter.

Interior passageway 82 in the body 62 communicates between the cylinder of the retrieval piston-cylinder arrangement 74 and a return lumen of the catheter 60. At the distal end portion of the catheter, the return lumen communicates with the principal lumen to provide a closed circulation path for the liquid that dispatches and retrieves the treating elements.

In addition, the body 62 has a third interior passageway 84 that communicates between guide wire inlet 86 and a guide wire lumen of the catheter 60. By itself, the catheter 30 may not have sufficient strength or torsional rigidity for insertion along a lengthy serpentine vascular path -- in typical angioplasty procedures, the distance between the percutaneous entry point and the coronary artery may be approximately 3-4 feet (90-120 cm). To assist in positioning the distal end of the catheter at the desired location, the catheter may be advanced over a guide wire that is pre-inserted to the desired location in a manner well known to those skilled in performing angioplasty and similar procedures. The guide wire inlet preferably includes

a Touhy-Borst valve or similar known device to close the guide wire inlet around the guide wire to restrict leakage of blood or other fluid from the guide wire lumen.

In use, the interior passageways, piston-cylinder arrangements, and catheter principal and return lumen are filled with sterile water or saline through the liquid inlet port 78 and one-way valve 80. In the initial position, the dispatch and retrieval piston-cylinders are oppositely positioned, with the piston of the dispatch piston-cylinder 72 in a withdrawn position, as shown in Figure 2B, and the piston of the retrieval piston-cylinder 74 in an advanced position, also as shown in Figure 2B. Before the treating elements can be moved to the desired position, gate 70 controlling the central bore must be opened.

By advancing the dispatch piston, the liquid in the dispatch cylinder is forced through the interior flow path 76 and into the central bore 68 containing the treating elements 22. The pressurized liquid flow ejects the treating elements from the central bore and forces the treating elements along the principal lumen of the catheter to the distal end portion located at the site to be treated. As liquid moves along the principal lumen in a distal direction, it displaces an equal amount of liquid that returns along the return lumen and enters the cylinder of the retrieval piston-cylinder arrangement 74, pushing the retrieval piston outwardly.

Retrieval of the treating elements may be accomplished by reversing the steps described above. The retrieval piston is advanced, forcing liquid in a reverse or distal direction along the return lumen and returning the fluid to the body along the principal lumen. The liquid flow moves the treating elements in a proximal or return direction along the principal lumen, returning them to the central bore of the body 62. The returning liquid enters the cylinder of the dispatch piston-cylinder arrangement 72.

With the catheter system as shown in Figure 2B, a completely closed system is provided, and no liquid that contacts the treating elements is allowed to enter the patient's body.

This may be particularly important when the treating agent is radioactive. The closed system arrangement also allows the treating elements, whether a single element or a train of treating elements, to be shifted back and forth slightly while in the distal portion of the catheter by alternately slightly depressing the dispatch and retrieval pistons. This technique may be used to provide a more uniform exposure of the selected vessel area, particularly where there is dead space between or at the ends of the treating elements.

A variation on the catheter system of Figure 2B is depicted in Figure 2C. The catheter system 88 shown there similarly includes a combination pump and loading device 90 and a multi-lumen catheter 92. The combination pump and loading device 90 also has a body portion 94 with a distal end portion 96 attached to the catheter 92, and a proximal end portion 98. In this embodiment, however, liquid inlet port 100, guide wire inlet 102 and dispatch and retrieval bellows 104 and 106, respectively, are located on one side of the body 94. This arrangement permits a large cylindrical chamber 108 to be provided, extending inwardly from the proximal end of the body, for receiving a carrier or insert 110 which is pre-loaded with treating elements 22. Alternatively, the body 94 and insert 110 could be of one piece or integral construction.

Insert 110 has a central bore 112 in which the treating elements are located, a gate 114 controlling passage of the treating elements from the central bore, and a laterally extending branch 116 of the central bore. When inserted into the chamber 108 of the body 94, central bore 112 of the insert 110 is aligned with central passageway 118 of the body 94, which communicates directly with a principal lumen of the catheter 92, and branch 116 communicates with internal passageway 120 of the body, which connects to the liquid inlet port 100 and the dispatch bellows 104.

Alternatively, the insert 110 could have a plurality of bores and be rotatably mounted in the body for selective alignment of the bores with inlet port 100 and central passageway 118. In this arrangement, one bore could be empty for fast

priming of the system and another bore could contain the treating elements.

As with the embodiment in Figure 2B, an internal liquid flow passageway 122 is provided in the body 94, communicating between the retrieval bellows and a return lumen of the catheter 92, and a guide wire passageway 124 is provided between a guide wire lumen of the catheter and guide wire inlet 102. Also similarly, a vent 126 is provided in communication with the passageway that connects with the liquid inlet port 100.

In operation, the catheter system of Figure 2C is essentially identical to that discussed regarding Figure 2B. The embodiment of Figure 2C allows the treating elements to be conveniently stored separately from the remainder of the catheter system, for example in special radiation-proof containers.

It should be clear that in each of the embodiments discussed above, the body, carrier (insert or carriage) and catheter may be provided in various combinations of assemblage, as a matter of choice. For example, the body and carrier could be preassembled or even of one piece construction. Similarly, the body could be preassembled with the catheter tube, with the carrier separate for convenient storage and transportation of the treating elements. Alternatively all three elements could be separate and assembled in the desired configuration on site -- this would permit the physician to select the appropriate combination depending on the desired procedure.

For radiation exposure of the desired site, the treating elements 22 contain radioactive material, preferably beta-emitting. In the preferred embodiment shown in Figure 3, the treating elements are elongated hollow cylinders 128 which are preferably constructed of stainless steel, silver, titanium or other suitable material, and are ideally in the range of 2.5 to 5.5 mm in length. The cylindrical treating elements have rounded first and second ends with a chamber 130 extending therebetween. The inner diameter of chamber 130 is preferably in the range of 0.4 to 0.6 mm. A first end plug 132 closes the first end of the cylinder, while a second end plug 134 closes the second end. The

end plugs are preferably less than about 1 mm in width and are affixed to cylinder 128, for example, by welding.

The outer diameter of the treating elements is preferably between approximately 0.6 and 0.8 mm, being sized, of course, to slidably fit into the respective receiving bores of the carriages, bodies and catheter lumen described above. To permit maximum mobility through the loading devices and catheters described above, the inner diameter of each of the bores or lumens the treating elements pass through should preferably be less than twice the outer diameter of the cylindrical treating elements and the outer surface of the treating elements may be coated with Teflon material or similar low-friction material to reduce friction between the treating element and the wall of the lumen in which it moves. This allows the treating elements to move quickly through the lumen, minimizes unnecessary exposure of other tissue to the treating elements and in particular minimizes radiation exposure to other tissue. Additionally, to increase the surface area of the treating elements subject to the motive force provided by fluid being passed through the system, the treating elements may also be provided with one or more annular ridges which extend outwardly about the circumference of the treating elements.

To treat a length of vascular tissue, a plurality of treating elements, joined together to form a train of treating elements, as illustrated in the attached figures, may be used. To keep the treating elements uniformly spaced from each other, and, more importantly, to prevent the treating elements from becoming too spaced apart while moving through the catheter, the individual treating elements may be connected by several lengths of hard tempered spring wire 136, as is shown in Figure 3.

Each treating element 22, as constructed above, encapsulates a therapeutic agent, such as a radiation emitting substance 138. Radiation emitting substance 138 is contained within interior chamber 130 of the treating element and may be composed of any alpha, beta or gamma particle emitting substance. Preferably, however, the radioactive source is a pure beta-particle emitter,

or beta and gamma emitter. Examples of such substances include Strontium⁹⁰, Ruthenium¹⁰⁶, Phosphorus³², Iridium¹⁹², and/or Iodine¹²⁵.

The amount and strength of the radioactive material contained in the combined number of treating elements 22 should be sufficient to deliver a desired dosage of from 100 to about 10,000 rads, preferably about 700 to 5,000 rads, in about 2-10 minutes. Radioactivity is generally measured in units of "Curie" (Ci), and the radioactivity of the material for the present invention is selected to provide the above dosage. For the preferred dosage, the radioactive material may have a radioactivity of approximately 0.45 and 25,000 mCi per centimeter of vessel to be treated, depending on the radiation source used. As described briefly earlier, when a train of treating elements is used which have dead space (non-radioactive) between adjacent elements, the train may be oscillated by moving the catheter slightly back and forth or by briefly repeatedly reversing the flow of liquid, resulting in a shifting back and forth of the treating elements to provide a more uniform radiation exposure of the selected area of the vessel.

The selected radioactive material may be contained within glass, foil, or ceramics, or, alternatively, within a powder or liquid medium, such as microparticles in liquid suspension. When solid materials are used, the preferred outer diameter of the material is approximately 0.5 mm, allowing it to be inserted into the central chamber 130 of the treating element cylinder 128. Such radioactive materials may be formed into pellets, spheres, and/or rods in order to be placed into the chamber of the treating element.

Various alternative treating elements may also be used to contain the radioactive material without departing from the present invention. For example, the treating elements may be toroidal, spherical, or in the form of elongated rings, and in such configurations, the radioactive material may be actually impregnated in a metal and formed into the desired shape. Alternatively, a radioactive powder may be fired to fuse the material so that it may be formed into the desired shape, which may then be encapsulated in metal, such as titanium, stainless

steel or silver, or in plastic, as by dipping in molten or uncured plastic. In still another embodiment, the treating elements may be formed from a ceramic material which has been dipped in a radioactive solution. In a still further
 5 alternative, the treating elements 22 may be constructed in the form of two piece hollow cylindrical capsules having a larger-diameter half with a central cavity and a smaller-diameter half also having a central cavity, the smaller half slidably received within the larger half and bonded or welded to form the capsule
 10 structure.

Turning now to a more detailed description of the catheters of the present invention, as stated previously, catheters of the present invention may be pre-attached to the loading device or, as discussed with regard to Figure 2, a fitting such as 38 may be
 15 provided for attaching an elongated catheter tube to the loading device. Although catheters of the present invention may vary in the number of lumens or the specific construction of such lumens, those catheters have in common, a proximal end attachable to a body member such as body 26, a distal end opposite the body which
 20 is adapted to be positioned at a selected site in the body, and an elongated tubular portion therebetween. For those catheters that are not pre-attached to the loading device, the proximal end may be provided with a keyed fitting to allow attachment of only certain catheters to the fitting on the loading device. Such
 25 fittings may include those generally known in the art which will not be discussed herein, but also may include specially designed fittings which would be peculiar to this device. A specially keyed fitting would prevent the inadvertent attachment of the fitting or body to other catheters on the market which are not
 30 specifically designed to receive the treating elements and/or to prevent the treating elements from being released into the body.

As used herein, the terms "elongated tube," "elongated catheter tube" and similar phrases are intended to include a catheter possessing one or more lumens produced from a single
 35 extrusion and catheters of multiple lumens wherein the catheter is made up of several separate tubes bundled together.

Figure 4 depicts the distal end portion of one catheter of the present invention, generally at 140, with the treating elements located in the distal end portion. In this embodiment, the catheter comprises a single tubular member 142 having a proximal end portion (not shown), a distal end portion and a lumen 144 extending therebetween. The tubular member is preferably extruded from Nylon 11 material, although other suitable plastic materials may be used. The outer diameter of the tubular member is sized according to the intended application -- for example 5 French or smaller for use in treating the stenotic site of a coronary artery. The inner diameter of the lumen is correspondingly sized to receive the treating elements 22.

To prevent treating elements 22 from exiting the distal end of the tubular member, a retention projection may be provided in the lumen to block passage of the treating elements, such as an end barrier 146. Barrier 146 is a separate molded tip adhered or bonded to the distal end portion of tubular member 142. Barrier 146 preferably has a smooth rounded external surface to minimize possible abrasion to a vessel or other tissue and a central opening 148 to allow liquid flow therethrough.

To aid in placement of the catheter at the desired location, a marker band 150 is attached to the outer surface of tubular member 142 at the distal end portion. To provide a continuous smooth outer surface, a slight undercut may be provided in the surface of the catheter tube, in which the marker band resides. Although shown on the exterior surface of the catheter, the marker band may also be provided internally as well. Preferably the barrier 146 and marker band 150 are constructed from barium, a platinum-iridium compound, or like substance, which is visible by fluoroscope during placement of the catheter.

In use, still referring to Figure 4, the distal end portion of the tubular portion is introduced into the body of a patient into a selected site, such as the coronary artery 152 following balloon angioplasty. In such instances, a guide wire will typically be pre-positioned in the patient, although a guiding catheter could also be used. The distal end of the catheter is

then advanced over the guide wire, through lumen 144. The positioning of the device is made more precise due to the ability to fluoroscopically observe the barrier 146 and marker band 150 at the distal end portion of the catheter tube.

5 After the distal end portion of the catheter is positioned such that the previously stenosed area, generally at 154, of the coronary artery is located between the barrier 146 and marker band 150, the guide wire can be removed, and the proximal end of the catheter can be connected to a treating element loading
10 device and/or pump, as described earlier with reference to the Figure 2-2B embodiments.

So connected, the treating elements 22 are in direct communication with lumen 144 of the catheter and a flow path is formed therebetween. Pressurized liquid, such as from a fluid
15 pump, syringe or other piston-cylinder arrangement, plunger, or elevated saline solution container, is then directed against the treating elements, causing them to advance along the catheter lumen until stopped by the end barrier 146.

Referring to the Figure 2A embodiment of a loading device as
20 an example, to move the treating elements 22 from the body 26 to the selected site in the patient, the carriage 48 is moved from the first position to the second position. This releases the treating elements into the flow path where they are carried rapidly by the motive force of the fluid therein into and through
25 the lumen of the catheter to the distal end portion, which is located at the stenotic site. The rapid transportation of the treating elements reduces the amount of radiation which is transmitted to tissues in the body through which the elongated catheter tube extends. In this embodiment, the liquid
30 transporting the treating elements exits through the central opening 148 in the end barrier 146.

As noted above, upon reaching the distal end portion of the elongated tube, the treating elements are prohibited from being ejected into the patient by the barrier 146. Once more, the
35 barrier and marker band may be used to fluoroscopically visualize the released radioactive elements, and account for their location. The barrier and marker band may be specifically spaced

to cover the distance of the lumen occupied by the total length of the radioactive treating elements, and the location of the elements may be confirmed by viewing a solid image between the barrier and marker band on the fluoroscope.

To maintain the treating elements within the distal end portion of the elongated tube, a constant fluid pressure through the lumen and against the treating elements may be required to counteract the effects of external blood pressure and/or gravitational forces exerted upon the treating elements, depending on the angle at which the distal end portion of the elongated tube is placed and on the specific location in the patient.

Preferably, in order to sufficiently irradiate the stenotic site of a coronary artery that has been subjected to PTCA to inhibit intimal hyperplasia, the treating elements should remain at the selected site for a sufficient time to deliver a therapeutically effective amount of radiation, which is preferably between about 100 and 10,000 rads, preferably about 700 to 5,000. The length of time required to deliver this dosage of radiation depends primarily on the strength of the radioactive source used in the treating elements and the number of treating elements employed. The radioactivity needed will depend on the strength of the source used and the emission, and may be in the range of 0.45 to 25,000 mCi depending on the source. After sufficient time, such as 2 to 10 minutes, has been allowed for treatment, the treating elements may be removed by withdrawing the catheter from the patient or by applying suction (such as by a syringe) to the proximal end of the lumen in which the treating element travels.

Another embodiment of an elongated catheter tube 156 of the present invention is shown in Figure 5. The proximal end of the catheter tube may be pre-attached to a loading device/pump or employ a fitting for keyed attachment to such a device, as described in detail earlier. Accordingly, only the distal end portion of the catheter is depicted in Figure 5.

As shown in Figure 5, the elongated tube 156 comprises co-axial inner and outer tubes 158 and 160 respectively. Inner tube

158 defines an inner bore or lumen 162, through which the treating elements 22 are advanced. Inner and outer tubes are spaced apart to define a return lumen 164 therebetween for return of the liquid used to advance the treating elements.

5 The distal end of the outer tube 160 tapers to a narrow, flexible and atraumatic tip 166 bonded to the outer tube. A radiopaque barrier 168 located slightly beyond the end of the inner tube 158 closes the outer tube 160 and blocks further proximal movement of the treating elements 22. Similarly to
10 marker band 150 of the previous embodiment, a marker band 170 may be provided in an undercut area on the surface of outer tube 160 at a location spaced proximally from the barrier 168 to enhance placement of the distal end portion and the treating elements at the desired location.

15 When used to treat the site of a coronary artery where a balloon angioplasty procedure has been carried out, this catheter 156 is positioned in the previously stenosed site by a guide tube or similar device. Positioning of the distal end portion of the catheter may be viewed fluoroscopically due to the radiopaque
20 barrier 168 and marker band 170.

 If not pre-attached to a loading device/pump, the proximal end of the catheter is attached to such a device as described earlier. Without unnecessarily repeating earlier description, the treating elements 22 are advanced along the inner lumen 162
25 of the catheter under the force of liquid flowing therethrough. With this embodiment, instead of exiting from the distal end of the catheter, the liquid exits from the distal end of the inner lumen (or through a side aperture 172 in the wall of the inner tube), and returns through the return lumen 164 provided between
30 the inner tube and the outer tube. The return liquid may be allowed to exit through the loading device/pump or may be collected therein, as described earlier, for alternative disposal.

 Unlike the first embodiment, this embodiment is a completely
35 closed system, in that the fluid is not released into the patient and the treating elements 22 do not contact the blood. While this eliminates the effects of blood pressure in moving the

treating elements, a small but constant fluid flow may be required to maintain the treating elements in the distal end portion of the elongated catheter tube due to the gravitational effects in the event the treatment site is at a higher elevation than the proximal end of the catheter. By oscillating the liquid flow between the dispatch and retrieval pistons, the train of treating elements 22 may be shifted slightly back and forth to make the exposure along the desired area more uniform.

The radioactive treating elements remain in the distal end portion of the elongated tube for a sufficient period of time to deliver a therapeutically affective amount of radiation. As was previously discussed, this is preferably about 100-10,000 rads, in the case of inhibiting the development of intimal hyperplasia.

After a sufficient amount of radiation is delivered, the treating elements 22 may be retrieved from the distal end portion of the elongated catheter tube and returned to the loading device by introducing pressurized fluid into the return lumen. This reverses the flow of liquid and creates an oppositely directed motive force on the treating elements forcing them proximally through the inner lumen 162 for return to the loading device. The elongated catheter tube may then be removed from the patient and the procedure concluded. Alternatively, the treating elements may be removed by withdrawing the catheter from the patient.

In a third alternative embodiment of the present invention shown in Figures 6A and 6B, the catheter is constructed and operates similarly to that described for the Figure 5 embodiment. Elongated catheter tube 174 comprises co-axial inner and outer tubes 176 and 178 respectively. Inner tube 176 defines an inner bore or lumen 180, through which the treating elements 22 are advanced. Inner and outer tubes are spaced apart to define a return lumen 182 therebetween for return of the liquid used to advance the treating elements.

The distal end of the outer tube 178 is not tapered, but is closed by radiopaque solid tip 184, which also serves as a barrier to the treating elements as they move along the inner lumen 180. Also similarly, a marker band 186 is provided on the surface of outer tube 178 at a location spaced proximally from

the tip 174 to enhance placement of the distal end portion and the treating elements at the desired location.

The initial placement of the distal end portion of elongated catheter tube 174 is facilitated by the use of a third or guide tube 188, as is shown in FIG 6B. As shown therein, the
 5 separate third tube 188 has a proximal end portion (not shown), a tapered distal end portion and a lumen 190 extending therebetween.

In use, the guide tube has sufficient strength or rigidity
 10 for placement or is placed into the body of a patient over a pre-positioned guide wire, so that the distal end portion of the third tubular member is located at a specific selected site within the body at which treatment is desired. Once the guide tube is positioned at the selected site, and the guide wire at
 15 least partially pulled back, the elongated catheter tube 174 shown in Figure 6A may be inserted into lumen 190 of the guide tube.

As in the Figure 5 embodiment, the embodiment shown in Figures 6A and 6B allows treating elements 22 to be hydraulically
 20 moved between the proximal and distal end portions of the elongated tube, with the direction of the hydraulic flow being determined by the pressure gradient existing between the delivery and retrieval lumens. Thus, after maintaining the treating
 25 elements at the distal end portion of the elongated catheter tube for a desired period of time, the treating elements may be retrieved by reversing the flow of fluid through the elongated tube. Following this the catheter and third or guide tube may be removed from the patient and the procedure concluded.

Another embodiment of the catheter of the present invention,
 30 particularly intended for placement at a desired location by advancement over a guide wire, is shown in Figures 7A and 7B. The elongated catheter tube 192 comprises a pair of inner tubes 194 and 196 that extend in a parallel side-by-side arrangement within an outer tube 198. Inner tube 194, which is of smaller
 35 diameter than tube 196, defines an inner lumen 200 for receiving a guide wire used for placement of the catheter at the desired location within the patient. Inner tube 196, which is of larger

diameter, provides inner lumen 202 along which the treating elements 22 travel. Return lumen 204 is provided by the space between the inner surface of the outer tube 198 and the outer surfaces of the inner tubes 194 and 196 for return flow of liquid used to transport the treating elements.

As seen in Figure 7A, the outer tube 198 has an open tapered distal end. An interluminal wall 206 is provided within the outer tube at the beginning of the taper and at the distal end of the inner tubes 194 and 196. The wall 206 includes an aperture in sealed communication with lumen 200 of inner tube 194, through which a guide wire may pass. The wall 206 is preferably slightly spaced from the distal end of the other inner tube 196, through which the treating elements pass, to allow liquid to exit from the end of tube 196 for return through the return lumen 206. The wall also provides a barrier to prevent the treating elements from exiting the end of tube 196.

As in the earlier embodiments, the elongated catheter tube 192 has first and second radiopaque marker bands, 208 and 210 on the outer tube to aid in placing the distal end portion at the desired location in the patient. As noted earlier, although generally depicted on the outer tube in many of the embodiments, the markers may be provided inside the catheter at any convenient location, such as on an inner tube or surface, without departing from the present invention.

In use for treating a stenotic site in a coronary artery with radiation, the proximal end of the elongated catheter 192 tube may be pre-connected to a loading device/pump or separately connected to such a device by a keyed fitting or similar arrangement, as discussed earlier. The distal end portion of the elongated catheter tube is then positioned at the selected site within the body of the patient by advancing the catheter over a pre-positioned guide wire. In this embodiment, the guide wire may be allowed to remain in position. This has the significant advantage that it is unnecessary to insert the guide wire a second time if a further catheter or device needs to be inserted after the treatment is completed.

The radiopaque marker bands 208 and 210 are visible on a fluoroscope and aid in the placement of the device. When the distal end portion of the elongated tube is positioned such that the selected site is located between marker bands 208 and 210, liquid may be pumped through the lumen 202 to move the treating elements to the distal end portion of the elongated catheter tube, where they are accounted for by the positioning of the marker bands. After sufficient irradiation has occurred, the flow through the device is reversed by reversing the flow of pressurized fluid through the return lumen causing return of the treating elements to the loading device. The elongated catheter tube may then be removed from the patient and the procedure completed.

A further alternative embodiment of the catheter of the present invention, preferably intended for placement over a guide wire, is shown in Figures 8A and 8B. The elongated catheter tube 212 comprises a pair of inner tubes 214 and 216 that extend in a parallel side-by-side arrangement within an outer tube 218. As in the Figure 7 embodiment, inner tube 214, which is of smaller diameter than tube 216, defines an inner lumen 220 for receiving a guide wire used for placement of the catheter at the desired location within the patient. Inner tube 216, which is of larger diameter, provides inner lumen 222 along which the treating elements 22 travel. A return lumen 224 is provided by the space between the inner surface of the outer tube 218 and the outer surfaces of the inner tubes 214 and 216 for return flow of liquid used to transport the treating elements, in the very same manner as depicted in Figure 7B. In the Figure 8 embodiment, however, inner tube 214 (for the guide wire) extends fully along the length of the outer tube 218, and is bonded to the outer tube at the distal-most location, where the outer tube is tapered.

In Figure 8A, an internal barrier 226 is provided at the end of the inner tube 216, through which the treating elements are carried, to block the passage of treating elements from the distal end of the tube 216. A center opening in the barrier 226 allows liquid to pass from the lumen 222 of the inner tube 216 to the return lumen. Alternatively, the barrier may be solid as

depicted with barrier 228 in Figure 8B (which is otherwise the same as Figure 8A), and an aperture 230 may be provided in the wall of inner tube 216 to permit liquid to flow between the treating element lumen 222 and the return lumen. Although not depicted in Figures 8A or 8B, it should be understood that the elongated catheter tube may also include a series of marker bands appropriately placed along the length of the tube to aid in accurate placement in the patient.

Another embodiment of the catheter of the present invention is shown in Figure 9. As shown there, catheter 232 has three coaxial tubes, inner tube 234, outer tube 236 and intermediate tube 238, which all extend the full length of the catheter. Inner tube 234 has a lumen 240 for receiving a guide wire for placement of the catheter at the desired location in the patient. Inner tube 234 is spaced from intermediate tube 238 to define an annular treating element passageway 242 therebetween. In this embodiment, the treating elements are preferably ring shaped, as at 244, or donut shaped, as at 246, to allow them to slide over the inner tube 234 and along the passageway 242. To provide a return flow channel, the inner diameter of the outer tube 236 is slightly larger than the intermediate tube 238 to provide a return flow path 248 therebetween.

The end of the catheter is closed by a molded tip plug 250, preferably of radiopaque material, bonded to the ends of the inner and outer tubes 234 and 236. Center passageway 252 through the tip plug allows for the passage of a guide wire or the like for placement of the catheter at the desired location. The distal end of the intermediate tube 238 stops short of the tip plug, thereby allowing the treating element passageway 242 to communicate directly with the return flow path 248. Radiopaque marker bands, although not shown, may also be incorporated on the distal end portion of the elongated catheter tube to aid in placing the elongated tube within the body at the selected site.

After the distal end portion of the elongated tube is positioned at the desired location in the patient, a liquid, such as saline, is forced through the treating element passageway 242 and directed against the ring-shaped treating elements, moving

the treating elements along the passageway over the inner tube 234 until they abut the distal tip plug 250. The radioactive elements are retained at the distal end portion of the elongated catheter tube for a sufficient time to deliver the therapeutically effective amount of radiation to the selected site. To retrieve the treating elements, the fluid flow is reversed through the flow path by forcing liquid in a distal direction through the return lumen. Following this the elongated tube can be removed over the guide wire and the procedure completed.

In a still further embodiment of the present invention, shown in Figure 10, a catheter 254 is provided which includes both an inflatable balloon membrane 256 for carrying out a balloon angioplasty procedure and treating elements 22 fixed in the distal end of the catheter for simultaneous treatment. The catheter of Figure 10 includes an elongated tubular portion 258, typically of extruded construction, with a guide wire lumen 260 and an inflation lumen 262. A balloon membrane is located at the distal end of the catheter tube and sealed to the exterior surface to form an inflatable balloon. Port 264 communicates between the inflation lumen and the inside of the balloon for inflating the balloon by pressurized liquid. Only the distal end portion of the catheter is shown -- the proximal end of the catheter being typical of angioplasty catheter construction as is well known to those skilled in the field

To perform radiation treatment simultaneously with a balloon angioplasty procedure, radioactive treating elements 22 are located within the balloon, between coaxial walls 266 and 268 of the distal end portion of the catheter. The treating elements are ring-shaped or donut-shaped, as described earlier, and positioned over the inner wall 266. Stop rings 270, preferably of radiopaque material, are positioned at each end of the string of treatment elements to maintain the treatment elements at a fixed location within the balloon and aid in locating the catheter at the desired location.

The strength and other characteristics of the radioactive treating elements are essentially as described earlier and will

not be repeated. With this construction, the balloon angioplasty procedure and the radiation treatment of the stenotic site may be carried out simultaneously instead of sequentially, thereby further reducing the time, cost and risk associated with such procedures.

In use, catheter 254 is positioned into the stenosed area of the artery over a pre-positioned guide wire. Using the radioactive treating elements alone or in conjunction with the radiopaque end rings, the distal end portion of the catheter is positioned such that the balloon portion is located at the stenosed site. Pressurized fluid introduced into the proximal end of the inflation lumen, as with a syringe, enters through port 264, inflating the balloon. The expanding balloon membrane 256 compresses the sclerotic plaque and increases the diameter of the blood vessel. The balloon may be deflated and the distal tip retained in this position for the desired period of time to deliver an effective amount of radiation to the previously stenosed area. The device may then be removed from the patient and the procedure completed.

Figure 11 shows a variation of the radiation delivery system of Figure 10. In the Figure 11 embodiment, the basic operation and construction of the catheter are the same as described with respect to that shown in Figure 10, except that in Figure 11, the radioactive treating elements are located on inner tube 272 and directly below balloon membrane 274. Balloon membrane may be inflated by the introduction of pressurized fluid through inflation lumen 276 defined between inner tube 272 and co-axial outer tube 278.

Figure 12 shows the distal end portion of another balloon catheter 280 embodying the present invention. The catheter 280 employs three coaxial tubes, inner tube 282, outer tube 284 and intermediate tube 286. Inner tube 282 defines an inner lumen 288 through which a guide wire may extend for placement of the catheter at the desired location. The space between the inner tube and the intermediate tube 286 defines an annular lumen 290, through which ring-shaped or donut-shaped treating elements may pass. The space between the intermediate tube and the outer tube

284 forms a return lumen 292 for return of liquid used to transport the treating elements.

The catheter 280 also includes a balloon membrane 294 bonded at one end to the exterior surface of the outer tube 284 and bonded to the exterior surface of the inner tube 282 (which extends beyond the distal ends of the intermediate and outer tubes) at the other end. The distal end of the outer tube is closed by a barrier 296, which may be radiopaque, to block the exit of the treating elements from the distal end of lumen 290.

In this embodiment, the same liquid used to transport the treating elements is also used to inflate the balloon membrane, although that is not required if a separate inflation lumen were provided. To inflate the balloon membrane, a side opening 298 or port is provided in the wall of the outer tube 284 and also in the intermediate tube 286 if desired. With this construction, pressurized blood-compatible liquid, such as sterile saline, may be used to advance the treating elements while simultaneously advancing the treating elements to the distal end portion of the catheter. The treating elements may be retrieved by reversing the flow of the liquid through the return and treating element lumen 292 and 290, respectively. Further release of pressure exerted upon the liquid will allow the balloon to deflate and the catheter to be removed.

Figure 13 illustrates a still further embodiment of a balloon catheter 300 which has a pair of adjacent parallel inner tubes, 302 and 304, forming guide wire lumen 306 and a treating element lumen 308. In a manner similar to Figures 7 and 8, the inner tubes are contained within an outer tube, and the interior space therebetween forms a return lumen. A balloon membrane 310 is bonded to the outer surface of the outer tube, forming an inflatable balloon. The balloon membrane may be inflated, through side port 312 in the wall of inner tube 304, by the same blood-compatible liquid that is used to propel the treating elements along the lumen 308. As in Figure 12, this catheter permits expansion of the balloon membrane to carry out an angioplasty procedure within a blood vessel at the same time the treating elements are being moved to the distal end portion of

the catheter (where the balloon is located) to effect radiation treatment of the tissue being subjected to the balloon angioplasty procedure.

Figure 14 shows a device that is essentially identical to that shown in Figure 2C and described in detail earlier, except that the body member 94 includes a latch 314, such as spring loaded pin, to retain insert 110 within chamber of cavity 108. A release mechanism 316 may also be provided to release the insert.

Figures 15A-15C show another embodiment of treatment delivery system that is similar in many respects to the embodiment shown in Figure 2C. In this embodiment, however, the gate 114 is in the form of a disc 318 pivotally mounted at the distal end of the insert 110. The disc includes a pair of spaced-apart apertures 320 and 322, of different sizes, therethrough, which may be moved into alignment with the center bore 112 of the insert. One of the apertures 320 is smaller in diameter than the treating elements 22, and when aligned with the bore 112 blocks the passage of treating elements from the bore while allowing liquid to pass therethrough for priming and the like. Alternatively, the disc may be pivoted to a position where the larger aperture 322 is aligned with the center bore 112, which allows the treating elements to be ejected from the insert by liquid flow pressure and advanced into and through the catheter. For shipment and storage, the disc may be positioned to fully cover the bore 112 of the insert.

In this embodiment, the body 94 includes a pair of opposed side access openings 324 for accessing the disc 318 to pivot it between the desired positions, and a pair of opposed viewing access openings 326 for visually verifying the location of the treating elements. In this embodiment, the catheter 92 has a proximal fitting 328 for attachment to the distal end of the body 94. This fitting may be keyed to assure that it is attached in the proper relationship to the body and the correct lumen of the catheter are aligned with the proper passageways of the body.

Figure 16 shows a simplified version of the treating system of the present invention. As shown there, the treating elements

22 are contained in a central passageway 330 of a solid body 332. Female luer lock connector 334 is provided at the inlet end of the passageway and male luer lock connector 336 is provided at the outlet end of the passageway, although a keyed fitting as described above also may be used.

During travel and storage a temporary female luer lock connector 338 is attached to the outlet connector 336. The connector 338 includes a pin 340 that extends from the connector into the passageway to hold the treating elements in place and provide a barrier against the escape of radiation. The inlet end of the passageway is smaller than the treating elements, thereby keeping the treating elements located in generally the center of the body 332.

To use this embodiment, the temporary connector 338 is removed and a female luer lock connector (or keyed connector, as discussed above) connector 342 at the proximal end of single lumen catheter 344 is attached to the outlet connector 336. A source, such as a syringe or suspended container, of blood-compatible liquid, such as saline, is attached to the inlet connector 334, and liquid is allowed to flow through the center passageway, ejecting the treating elements 22 and forcing them along the length of the catheter from the proximal to the distal end portion, which is presumable located at the site in the vascular system where treatment is desired. After the treatment is complete, the treating elements are removed by withdrawing the catheter from the patient's body or by applying a suction to the proximal end to return the treating elements by the force of reversed liquid flow.

Figure 17 is identical to Figure 12, except that a fourth co-axial outer tube 346 is provided over tube 284, and the end of the balloon membrane 294 is bonded to the outer tube 346 instead of the tube 284. The distal end of the outermost tube 346 terminates just inside the balloon membrane, and the space between the outermost tube 346 and the tube 284 provides an inflation lumen 348 through which pressurized fluid may flow directly into the area beneath the membrane to inflate the balloon. This construction allows a separate source of

pressurized fluid to be used to inflate the balloon membrane, and inflation of the balloon membrane is not dependent on the pressure of the liquid used to move the treating elements to the distal end portion of the catheter.

5 Similarly, Figure 18 is identical to Figure 13, except that an additional tube 350 is provided over the other tubes described in connection with Figure 13, and one end of the balloon membrane 310 is bonded to surface of the tube 350. As with Figure 17, the space between the additional tube 350 and the tubes described
10 earlier provides an inflation lumen 352, the distal end of which lumen opens directly in the area beneath the balloon membrane. This construction also allows a source of fluid, independent of the liquid used to move the treating elements, to be used to inflate the membrane in carrying out an angioplasty procedure.

15 Figure 19 shows a still further embodiment of the distal end portion of a catheter 354 having an elongated inner tube 356 (which extends from a proximal end portion, not shown) defining an inner lumen 358. The inner tube 356 extends co-axially within an outer tube 360, the distal end of which stops short of the
20 distal end of the inner tube. Balloon membrane 362 is attached at one end to the surface of outer tube 360 and is attached at the other end to the surface of the inner tube 356. The space between the inner and outer tubes forms an inflation lumen 364, through which liquid may be introduced to inflate the balloon.

25 A separate elongated catheter tube 364 is insertable into inner lumen 358 such that the distal end portion of the separate tube lies within the area of the balloon. The separate tube also has a lumen 366 extending from the proximal end (not shown) through which treating elements 22 are movable under the force of
30 flowing liquid from the proximal to the distal end portion of the catheter (the liquid in this embodiment exits through the distal end of the lumen 358).

35 Although the present invention has been described in terms of certain specific embodiments, it is understood that various changes and modifications may be made without departing from the present invention, and reference should be made to the appended claims to determine the proper scope of this invention.

CLAIMS

What is claimed is:

1. Apparatus for treating a selected area of the vascular system of a human patient comprising:

5 a) an elongated flexible catheter tube having a proximal end portion adapted to remain outside the patient's body, a distal end portion adapted to be positioned at a selected location within the vascular system of a patient, and a first lumen extending between said proximal end portion and said distal end portion, said catheter tube being of sufficiently small diameter for introduction into the vascular system of a human patient;

10 b) a port communicating with said first lumen at said proximal end portion for introducing a blood-compatible liquid thereinto;

15 c) a source of blood-compatible liquid in communication with said port for introducing said liquid under pressure into said port; and

20 d) a treating element positionable in said first lumen, said treating element being movable from said proximal end portion through said lumen and to said distal end portion of said first lumen by the motive force of the aforesaid liquid flowing through said first lumen.

2. The apparatus of Claim 1, wherein said first lumen is open at said distal end portion, and said apparatus further comprises a retention projection extending into said first lumen at said distal end portion of said first lumen, said projection being adapted to retain said treating element within said first lumen.

3. The apparatus of Claim 1, wherein said elongated tube includes a second lumen extending between said proximal and distal end portions, said second lumen being in communication with said first lumen at said distal end portion, the distal end portions of said first and second lumens being otherwise closed to the exit of fluid whereby fluid moves between said proximal

and distal end portions of said first lumen and returns along said second lumen, and whereby said treating elements are movable between said distal end portion and said proximal end portion of said elongated tube by the motive force of liquid introduced into said second lumen.

4. The apparatus of Claim 3, wherein said elongated tube includes a third lumen extending between said proximal and distal end portions, said third lumen being open at both end portions, and being adapted to receive a guide wire for aiding in positioning said elongated tube at the selected area in the body.

5. The apparatus of Claim 1, wherein said treating element is a source of radiation.

6. The apparatus of Claim 5, further comprising a pair of spaced apart radiopaque markers located on the distal end portion of said elongated tube and defining the effective treatment area therebetween.

7. The apparatus of Claim 5, wherein said treating element comprises a beta-particle emitting radioactive material.

8. The apparatus of Claim 1, further comprising:

a housing member, said housing member having a first end, a second end and a first bore extending within said housing member from said first end;

said elongated tube being attached to said first end of said housing member and said proximal end portion of said first lumen being in communication with said first bore at said first end;

said housing member being adapted for positioning said treating element within said first bore.

9. The apparatus of Claim 8, wherein said housing member further comprises a gate, said gate being movable between a first position and a second position wherein said treating element is released into said first bore.

10. The apparatus of Claim 1, further comprising:

a fluid pump operatively connected to said first lumen, said fluid pump adapted to control fluid flow through said first lumen.

11. A method for treating a selected area of the vascular system of a human patient comprising:

a) providing an elongated flexible catheter tube having a distal end portion adapted to be positioned at a selected area in the vascular system of the patient, a proximal end portion adapted to remain outside the body of the patient, a first lumen extending therebetween, and a port communicating with said first lumen at said proximal end portion for introducing a blood-compatible liquid thereinto;

b) introducing the distal end portion of the elongated catheter tube percutaneously into the vascular system of a patient;

c) advancing the distal end portion to a selected position in the vascular system;

d) introducing a treating element into said first lumen of said elongated catheter tube at said proximal end portion of said tube;

e) moving said treating element through said first lumen by flowing a blood-compatible liquid through said first lumen from the proximal end portion to the distal end portion of said tube, said liquid flow generating a motive force on said treating element to move said treating element from said proximal end portion through said lumen to said distal end portion;

f) allowing said treating element to remain at said distal end portion sufficient time for treatment of said selected area, during which time the remaining portion said elongated catheter tube is free of treating elements; and

g) withdrawing said elongated catheter tube from the body of said patient.

12. The method of Claim 11, wherein said elongated tube further comprises a second lumen extending between said proximal end portion and said distal end portion of said elongated tube, and further including the step of:

5 a) introducing an elongated guide wire having a proximal end portion and a distal end portion opposite said proximal end portion into the selected area of the body prior to introducing said first elongated tube, whereby said distal end portion of said guide wire extends to the selected area; and

10 b) advancing said second lumen of said elongated tube over said guide wire to move said distal end portion of said elongated tube to the selected area in the body.

13. The method of Claim 11, further comprising the step of:

5 a) introducing an elongated guide wire having a first end portion and a second end portion opposite said first end portion, into the selected area of the body prior to introducing said elongated tube, whereby said second end portion of said guide wire extends within the body and to the selected area;

10 b) inserting a guide tube having a proximal end portion, an open distal end portion and a lumen extending therebetween into the patient after introducing said elongated guide wire by advancing said guide tube over said guide wire until said second end portion of said guide tube is positioned within the body proximate the selected area;

c) removing said guide wire from said distal end portion of said guide tube; and

15 d) advancing said elongated tube into said lumen of said guide tube until said distal end portion of said elongated tube is positioned within the body within said lumen of said guide tube.

14. The method of Claim 11, wherein said treating element is radioactive and including allowing said radioactive treating element to remain at said distal end portion of said first lumen of said elongated tube for a sufficient period of time to expose

the selected area of the body to a therapeutically effective amount of radiation.

15. The method of Claim 14, wherein said therapeutically effective amount of radiation is between 100 and 10,000 rad.

16. The method of Claim 11, further comprising the step of retrieving said radioactive source from said distal end portion of said elongated tube prior to withdrawing said elongated tube from the body of the patient.

17. An elongated tube having a proximal end portion, a distal end portion opposite said proximal end portion and a lumen extending therebetween;

an inflatable balloon having a proximal end portion and a distal end portion opposite said proximal end portion; said end portion of said balloon being attached to said distal end portion of said elongated tube; and

a treating element being positioned at said distal end portion of said elongated tube within said balloon.

18. The apparatus of Claim 17, wherein said treating element has a proximal end and a distal end, and further comprising:

a first radiopaque marker located adjacent said distal end of said radioactive element; and

a second radiopaque marker located adjacent said proximal end of said treating element.

19. The apparatus of Claim 17 wherein said elongated tube has a second lumen extending between said proximal end portion and said distal end portion of said tube, said second lumen being in communication with said balloon to allow inflation of said balloon when pressurized fluid is introduced therethrough.

The method
20. An apparatus for irradiating a selected area of a coronary artery that has been subjected to a balloon angioplasty procedure, comprising:

providing an elongated catheter tube having a distal end portion, a proximal end portion, a first lumen extending therebetween, and a port communicating with said first lumen at said proximal end portion for introducing liquid thereinto;

5 introducing the distal end portion of the elongated catheter tube into the vascular system of a patient and advancing the distal end portion to the selected area in the coronary artery where the balloon angioplasty procedure has been carried out;

10 introducing a radioactive treating element into said first lumen at said proximal end portion of said elongated catheter tube;

15 moving the radioactive treatment element from said proximal end portion to said distal end portion of said elongated catheter tube by introducing a pressurized liquid into said first lumen at said proximal end portion of said tube to generate a motive force on the treating element;

20 allowing the radioactive treating element to remain in the distal end portion of said elongated catheter tube for a time sufficient to expose the selected area of the coronary artery with a therapeutically effective amount of radiation; and

removing the radioactive treating elements from the selected area within the coronary artery.

21. The method of Claim 20 wherein the elongated catheter tube comprises a second lumen extending between said proximal and distal end portions and communicating with said first lumen at said distal end portion for providing a return passageway for
 5 liquid employed in moving the radioactive treating element to the distal end portion, and wherein said radioactive treating element is removed from the selected area of the coronary artery by reversing the flow of liquid so that it flows from the proximal to the distal end portion of said second lumen and from the
 10 distal to the proximal end portion of said first lumen to provide a motive force for returning the radioactive treating element to the proximal end portion of the elongated catheter tube.

22. The method of Claim 20 wherein the radioactive treating element comprises beta-emitting radioactive material.

23. The apparatus of Claim 8 further comprising a separate carrier for the treating elements, said carrier being adapted for connection with said housing.

24. The apparatus of Claim 23 wherein said housing includes a dispatch passageway for communication of liquid to dispatch the treating elements, guide wire passageway for passage of a guide wire, and a third passage way for return of said liquid through the housing.

25. The apparatus of Claim 1, wherein said treating element comprises a plurality of treating elements flexibly joined in series to form a train of treating elements.

26. The apparatus of Claim 1 wherein the diameter of said first lumen is less than twice the diameter of the treating element.

27. The apparatus of Claim 17 in which the treating elements are fixedly disposed at said distal end portion.

28. The apparatus of Claim 17 wherein said tube includes a lumen extending between said proximal and distal end portions in which said treating elements are movable between said proximal and distal end portions.

TITLE:

METHOD AND APPARATUS FOR TREATING A DESIRED AREA
IN THE VASCULAR SYSTEM OF A PATIENT

INVENTORS:

RON WAKSMAN, M.D.
THOMAS D. WELDON
RICHARD A. HILLSTEAD
JONATHAN J. ROSEN
CHARLES E. LARSEN
IAN R. CROCKER, M.D.
RAPHAEL F. MELOUL

ABSTRACT OF DISCLOSURE

Apparatus and method are described for delivery of a treating element, such as a radiation source, through a catheter to a desired site in the vascular system of a patient, such as a coronary artery, for inhibiting the formation of scar tissue such as may occur in restenosis following balloon angioplasty. The apparatus includes an elongated flexible catheter tube having proximal and distal end portions, with a lumen extending therebetween, and a diameter sufficiently small for insertion in to a patient's vascular system. One or more treating elements, such as a capsule or pellet containing radioactive material, is positionable within the lumen and movable between the proximal and distal end portions under the force of liquid flowing through the lumen. A method for using such apparatus, including a method for using such apparatus simultaneously with a balloon angioplasty procedure, is disclosed.





FIG. 2B




FIG. 2C




FIG. 3




FIG. 4





FIG. 5






FIG. 6A




FIG. 6B

FIG. 7A

7B 210





FIG. 7B




FIG. 8A





FIG. 8B




$$\frac{F}{G} = \frac{F}{G}$$


FIG. 12




FIG. 13 is a cross-sectional view of a device 300, showing a central core 22, a surrounding layer 302, and an outer layer 304. The device is shown in a bent configuration, with a curved section 306 and a straight section 308. The device is labeled 310.

FIG. 13





FIG. 14






FIG. 17




FIG. 18





FIG. 19



**DECLARATION AND POWER OF
ATTORNEY ORIGINAL PATENT APPLICATION**

As a below named inventor, I hereby declare that:

Type of Application

This declaration is for the following type application:

<u> X </u>	Original
<u> </u>	National Stage of PCT
<u> </u>	Supplemental
<u> </u>	Divisional
<u> </u>	Continuation

Inventorship Identification

My residence, post office address and citizenship are as stated below next to my name, I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Method and Apparatus For Treating A
Desired Area in the Vascular System of a Patient

Specification Identification

The specification of which:

<u> </u>	is attached hereto.
<u> X </u>	was filed on <u>October 27, 1994</u> as Application Serial No. <u> </u> or United States Post Office Express Mail No. <u>EF872855385US</u> , as Serial No. not yet known, and was amended on <u> </u> (if applicable).
<u> </u>	was described and claimed in PCT International Application No. <u> </u> filed on <u> </u> and as amended under PCT Article 19 on <u> </u> (if any).

Acknowledgement of Review of Papers and Duty of Candor

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56, which provides:

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner described by §§ 1.97 (b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine; (1) prior art cited in search reports of a foreign patent office in a counterpart application, and (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

(b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

(1) it establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or

(2) it refutes, or is inconsistent with, a position the applicant takes in:

(i) opposing an argument of unpatentability relied on by the Office, or

(ii) asserting an argument of patentability. A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

(c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

- (1) each inventor named in the application;
- (2) each attorney or agent who prepares or prosecutes the application; and
- (3) every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.

(d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.

_____ In compliance with this duty there is attached an information disclosure statement, 37 CFR 1.97.

I do not know and do not believe that the invention was ever known or used in the United States of America before my or our invention thereof; I do not know and do not believe that the invention was ever patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application; I do not know and do not believe that the invention was in public use or on sale in the United States of America more than one year prior to this application; and the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to this application.

Priority Claim

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

 X No such applications have been filed.

 Such applications have been filed as follows.

Country	Application Number	Date of Filing (Month/Day/Year)	Priority Claimed	
			Yes	No

Power of Attorney

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Edward D. Manzo, Reg. 28,139
 Granger Cook Jr., Reg. 18,283
 Gary W. McFarron, Reg. 27,357
 Andrew G. Kolomayets, Reg. 33,723
 Ted K. Ringsred, Reg. 35,658

Donald E. Egan, Reg. 19,691
 Dean A. Monco, Reg. 30,091
 Stephen B. Heller, Reg. 30,181
 Mark J. Murphy, Reg. 34,225
 David M. Thimmig, Reg. 36,034

Send correspondence to:

Direct telephone calls to:

Gary W. McFarron, Esq.
 COOK, EGAN, MCFARRON & MANZO, LTD.
 135 South LaSalle Street, Suite 4100
 Chicago, Illinois 60603

Gary W. McFarron, Esq.
 (312) 236-8500

Declaration

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of

Inventor: Ron Waksman, M.D.

Residence Atlanta, Georgia

Citizenship Israel / U.S.A. R.W.

Post Office Address 2075 La Vista Road, #603, Atlanta, Georgia 30329

Inventor's Signature Ron Waksman M.D. Date 10/27/94

Full Name of

Inventor: Thomas D. Weldon

Residence Gainesville, Georgia

Citizenship United States

Post Office Address 4257 Tall Hickory Trail, Gainesville, Georgia 30506

Inventor's Signature Thomas D. Weldon Date 10/27/94

Full Name of

Inventor: Richard A. Hillstead

Residence Duluth, Georgia

Citizenship United States

Post Office Address 3485 Leaf Land Court, Duluth, Georgia 30136

Inventor's Signature Richard A. Hillstead Date _____

Full Name of

Inventor: Jonathan J. Rosen

Residence Alpharetta, Georgia

Citizenship United States

Post Office Address 1407 TreeRidge Parkway, Alpharetta, Georgia 30202

Inventor's Signature Jonathan J. Rosen Date 10/27/94


Full Name of

Inventor: Charles E. Larsen

Residence Cumming, Georgia

Citizenship United States

Post Office Address 6080 Cherokee Trace, Cumming, Georgia 30130

Inventor's Signature 

Date

10/27/94

Full Name of

Inventor: Ian R. Crocker, M.D.

Residence

Stone Mtn., Georgia.

Citizenship

Canadian.

Post Office Address

5071 Chedworth Drive, Stone Mtn, Ga. 30087

Inventor's Signature

Ian R Crocker M.D.

Date

10/27/94

Full Name of

Inventor: Raphael F. Meloul

Residence Atlanta, Georgia

Citizenship United States

Post Office Address 1341 Bramble Road, Atlanta, Georgia 30329

Inventor's Signature

Raphael F. Meloul

Date

10/27/94